Skip to content

Study · Animal study (in vivo) · rat · 2001

3 results

Maintenance of cortical bone in human parathyroid hormone(1-84)-treated ovariectomized rats.

Samnegård E, Iwaniec UT, Cullen DM, Kimmel DB, Recker RR

Bone1 Mar 2001Cited by 16 (Europe PMC)

PMID11248654 (opens in a new tab)DOI10.1016/s8756-3282(00)00446-4 (opens in a new tab)PepBankPUB-11248654
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized rats, hPTH increased cortical BMD, BMC, and endocortical bone formation versus intact controls.

    In plain wordsIn rats with ovaries removed, hPTH increased cortical bone measures versus intact controls.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    IncreaseCortical bone measures
    Study

    ratn: not reported in source

    ovariectomized rats
    Comparator
    intact controls
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    75 microg/kg per day on 3 days/week · subcutaneous · 12 weeksAs given in this study (rat).

    Source sentences

    Summary
    Treatment of ovx rats with hPTH for 12 weeks resulted in greater cortical BMD, BMC, and endocortical bone formation than in intact or ovx controls.
    1 context sentence
    Summary · context
    For the following 12 weeks, four groups received subcutaneous injections of hPTH (75 microg/kg per day on 3 days/week) and four groups received vehicle.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized rats, hPTH increased cortical BMD, BMC, and endocortical bone formation versus ovariectomized controls.

    In plain wordsIn rats, hPTH increased cortical bone measures versus controls with ovaries removed.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    IncreaseCortical bone measures
    Study

    ratn: not reported in source

    ovariectomized rats
    Comparator
    ovariectomized controls
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    75 microg/kg per day on 3 days/week · subcutaneous · 12 weeksAs given in this study (rat).

    Source sentences

    Summary
    Treatment of ovx rats with hPTH for 12 weeks resulted in greater cortical BMD, BMC, and endocortical bone formation than in intact or ovx controls.
    1 context sentence
    Summary · context
    For the following 12 weeks, four groups received subcutaneous injections of hPTH (75 microg/kg per day on 3 days/week) and four groups received vehicle.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In hPTH-pretreated ovariectomized rats, low-dose hPTH increased BMD, BMC, cortical area, and endocortical formation, and decreased marrow area versus controls.

    In plain wordsIn hPTH-pretreated rats, low-dose hPTH increased bone density, content, cortical area, and inner-surface formation, and decreased marrow area versus ovariectomized controls.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    MixedCortical bone maintenance measures
    Study

    ratn: not reported in source

    ovariectomized rats
    Comparator
    ovariectomized controls
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    25 microg/kg per day on 3 days/weekAs given in this study (rat).

    Source sentences

    Summary
    In ovx rats pretreated with hPTH and then treated with LowPTH, BMD, BMC, Ct.Ar, and endocortical bone formation were greater and Ma.Ar was smaller than in ovx controls.
    1 context sentence
    Summary · context
    For the following 12 weeks, four groups received subcutaneous injections of hPTH (75 microg/kg per day on 3 days/week) and four groups received vehicle.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.